Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st March 2026
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | -8.5% | -8.5% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | -8.5% | -8.5% |
The Liontrust GF Special Situations Fund returned -8.5% in Q1 2026 versus the FTSE All-Share's +2.4%, as Middle East conflict intensification drove market volatility. Energy holdings BP (+42%) and Shell (+32%) performed exceptionally as Brent crude doubled to $118/barrel due to Strait of Hormuz disruption. The manager owns these integrated oil companies for their essential infrastructure and capabilities, not as oil price bets. Conversely, smaller company holdings suffered from risk-off sentiment unrelated to fundamentals, with AI disruption fears affecting technology names like GlobalData (-35%) and Craneware (-30%). Despite this weakness, the manager maintains conviction in portfolio companies' competitive moats and notes the fund now trades at a significant P/E discount to the UK market (11.4x vs 12.7x) despite superior quality metrics. Healthcare holdings GSK and AstraZeneca delivered positive returns on strong results. M&A interest remains elevated, with Auction Technology Group rejecting opportunistic takeover approaches. The extreme valuation compression in quality smaller companies creates attractive long-term opportunities for patient investors.
The fund invests in high-quality UK companies with strong competitive advantages, focusing on smaller and mid-cap stocks that trade at attractive valuations despite superior fundamentals including high returns on capital, strong margins, and earnings stability.
The manager believes current evidence suggests they are within one of those instances where starting point valuations are at such extremities that the risk/reward opportunity for longer term investors is considerable. The fund's tilt towards higher quality smaller companies has been consistently applied for over two decades and tried and tested through various market conditions.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| May 11 2026 | 2026 Q1 | ATG.L, AZN.L, BP.L, CRW.L, DATA.L, GAMA.L, GSK.L, REL.L, SGE.L, SHEL.L, TCAP.L | AI, energy, oil, Quality, small caps, technology, Uk, valuation |
BP.L SHEL.L GAMA.L ATG.L |
Fund underperformed due to Middle East conflict driving risk-off sentiment that disproportionately hit smaller companies despite strong fundamentals. Energy holdings BP and Shell surged on oil price spike. AI disruption fears weighed on technology names. Portfolio now trades at significant discount to market despite superior quality metrics, creating compelling long-term opportunity. |
| Jan 15 2026 | 2025 Q4 | AJB.L, COA.L, DGE.L, NXT.L | compounders, Quality, rates, small caps, Uk, value |
BIG LN AJB LN IHP LN |
Quality growth stocks faced another tough month as UK markets favored Value sectors, but extreme valuation compression has created compelling opportunities. The Fund's high-quality compounders trade at historic discounts despite superior fundamentals, with free cash flow yields exceeding the broader market. Supportive macro conditions and rate cuts position Quality for inevitable leadership rotation. |
| Nov 17 2025 | 2025 Q3 | AZN.L, GSK.L, QLT.L, REL.L, WEIR.L | Data Analytics, Mining, Pharmaceuticals, small cap, technology, UK Equities | - | The fund underperformed in October despite strong pharmaceutical holdings GSK and AstraZeneca raising guidance. Technology holdings faced headwinds with leadership changes and margin pressure. The fund added Cohort while benefiting from supportive market conditions including moderating inflation and dovish monetary policy. Focus remains on UK special situations with earnings momentum. |
| Jul 16 2025 | 2025 Q2 | AJB.L, ALPH.L, AZN.L, BNZL.L, BP.L, CRW.L, MAB1.L, RWS.L, SHEL.L, SXS.L | Buybacks, industrials, M&A, small caps, special situations, United Kingdom, value |
BP.L SHEL.L BNZL.L AZN.L RWS.L |
UK special situations fund returned 3.4% in volatile Q2, underperforming on industrials exposure during tariff uncertainty but benefiting from small-cap recovery. Three top contributors gained on takeover interest including Spectris up 70%. Fund maintains conviction in smaller companies' compounding potential, expecting returns supported by ongoing M&A, buybacks and earnings growth despite recent sector headwinds. |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2026 Q1 |
OilBP and Shell performed exceptionally well as Brent crude oil prices doubled to $118 a barrel due to Middle East conflict disrupting the Strait of Hormuz. The fund owns these integrated oil stocks not as a bet on oil prices, but because they sit at the centre of an essential system with hard-to-replicate infrastructure and capabilities. |
Oil Energy Integrated Oil & Gas Geopolitical |
AITechnology and media holdings saw share price weakness driven by market concerns around AI disruption rather than any evidence of operational deterioration. The manager has devoted considerable time to research on AI impact and maintains conviction that the majority of holdings can maintain their competitive moat despite short-term market noise. |
AI Technology Disruption Software | |
Small CapsA number of holdings below the FTSE 100 suffered from weakening investor sentiment entirely unrelated to news flow or company fundamentals. The fund now trades at a significant P/E discount to the UK market despite displaying returns on capital twice that of the wider market and higher margins. |
Small Caps Valuation Quality UK | |
QualityGeopolitical and economic risks reinforce the importance of the portfolio's Quality attributes, with high returns on capital, high margins, strong solvency and earnings stability. Despite these attributes, the portfolio trades at a weighted average free cash flow yield of 9.6% versus benchmark at 7.4%. |
Quality Returns Margins Valuation | |
| 2025 Q4 |
QualityThe fund owns high-quality compounders with weighted average cash flow return on invested capital of 16.3% and operating margins of 19.7%. Despite reliable underlying trading performance, extreme valuation compression has left companies trading at 26% discount to historic averages. The case is building for rotation back to Quality given macro conditions. |
Quality Compounders Margins Valuation Rotation |
Small CapsUK market's poor relative returns for small and mid-cap stocks persisted as adverse headwinds throughout 2025. FTSE 250 mid-cap index returned only 2.9% in Q4 versus FTSE 100's 6.9%. FTSE AIM All-Share performance was negative at -1.7%. |
Small Cap Mid Cap FTSE Underperformance | |
ValueMarket was led by familiar Value areas with Basic Resources returning 19.7% in Q4 and Banks rising 17.6%. This represents continued concentration of gains in asset intensive sectors, creating headwinds for growth-oriented strategies. |
Value Basic Resources Banks Asset Intensive | |
| 2025 Q3 |
PharmaceuticalsGSK and AstraZeneca were top performers with strong earnings and guidance raises. GSK raised 2025 sales and earnings guidance after double-digit growth from specialty HIV and oncology drugs. AstraZeneca benefited from pricing agreement optimism and reiterated low double-digit core EPS growth guidance. |
Pharmaceuticals Oncology HIV Pricing |
DataMixed performance in data analytics companies. GlobalData cut second-half EBITDA margin guidance due to slower acquisition integration but showed 4% growth in contracted forward order book. RELX declined despite meeting expectations and reaffirming outlook. |
Data Analytics EBITDA Acquisitions Technology | |
| 2025 Q2 |
Small CapsThe fund maintains significant exposure to small and mid-cap companies, which led the market recovery from April lows. Of the 15 small cap and AIM-listed stocks in the portfolio, the average total return in Q2 was 12.6%, significantly outperforming the portfolio average. The fund remains resolute in its conviction that smaller companies retain highly attractive growth compounding potential over the longer term. |
AIM Recovery Compounding Growth Momentum |
BuybacksThe fund expects portfolio returns to continue being supported by ongoing buyback activity alongside M&A and earnings growth. Shell maintained its multi-billion-dollar buyback programme despite earnings pressures, while BP scaled back its quarterly buyback due to profit declines. |
Capital Return Shell BP Shareholder Returns |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | Fund Letters | Liontrust GF Special Situations Fund | BP.L | BP plc | Oil & Gas Integrated | Integrated Oil & Gas | Bull | New York Stock Exchange | cash generation, competitive moat, energy infrastructure, Global Networks, Integrated Oil, Operational Flexibility, Trading Optimization | Login |
| May 11, 2026 | Fund Letters | Liontrust GF Special Situations Fund | SHEL.L | Shell plc | Oil & Gas Integrated | Integrated Oil & Gas | Bull | New York Stock Exchange | cash generation, competitive moat, energy infrastructure, Global Networks, Integrated Oil, Operational Flexibility, Trading Optimization | Login |
| May 11, 2026 | Fund Letters | Liontrust GF Special Situations Fund | GAMA.L | Gamma Communications plc | Telecom Services | Alternative Carriers | Bull | New York Stock Exchange | cash generation, M&A Target, Share Buybacks, Small cap value, telecommunications, UCaaS, UK SME Market | Login |
| May 11, 2026 | Fund Letters | Liontrust GF Special Situations Fund | ATG.L | Auction Technology Group plc | Software - Application | Interactive Media & Services | Bull | New York Stock Exchange | cash generation, Cyclical Recovery, digital platform, Digitization, M&A Target, network effects, Online auctions | Login |
| Jan 15, 2026 | Fund Letters | Anthony Cross | BIG LN | Big Technologies plc | Industrials | Commercial Services & Supplies | Bull | New York Stock Exchange | Electronic Monitoring, international expansion, product innovation, Public safety, Recurring Contracts | Login |
| Jan 15, 2026 | Fund Letters | Anthony Cross | AJB LN | AJ Bell plc | Financials | Capital Markets | Bear | New York Stock Exchange | Investment Platforms, margin pressure, Marketing Spend, Net Inflows, Retail Investing | Login |
| Jan 15, 2026 | Fund Letters | Anthony Cross | IHP LN | IntegraFin Holdings plc | Financials | Capital Markets | Bull | New York Stock Exchange | Adviser Networks, Assets Under Administration, Investment Platforms, operating leverage, recurring revenue | Login |
| Jul 16, 2025 | Fund Letters | Liontrust GF Special Situations Fund | BP.L | BP plc | Energy | Integrated Oil & Gas | Bear | London Stock Exchange | buybacks, Commodity Exposure, energy, Integrated Oil, M&A Target, Oil & Gas, UK | Login |
| Jul 16, 2025 | Fund Letters | Liontrust GF Special Situations Fund | SHEL.L | Shell plc | Energy | Integrated Oil & Gas | Bear | London Stock Exchange | buybacks, Commodity Exposure, energy, Integrated Oil, LNG, M&A, Oil & Gas, UK | Login |
| Jul 16, 2025 | Fund Letters | Liontrust GF Special Situations Fund | BNZL.L | Bunzl plc | Industrials | Trading Companies & Distributors | Bull | London Stock Exchange | Distribution, Foodservice, Industrials, Operational Issues, UK, US Exposure, value opportunity | Login |
| Jul 16, 2025 | Fund Letters | Liontrust GF Special Situations Fund | AZN.L | AstraZeneca PLC | Health Care | Pharmaceuticals | Bull | London Stock Exchange | biotechnology, Drug-Pricing, Global distribution, IP Portfolio, Oncology, pharmaceuticals, UK | Login |
| Jul 16, 2025 | Fund Letters | Liontrust GF Special Situations Fund | RWS.L | RWS Holdings plc | Communication Services | Interactive Media & Services | Bear | London Stock Exchange | AI disruption, AIM Listed, life sciences, Patent Services, small-cap, Structural decline, Translation Services, UK | Login |
| TICKER | COMMENTARY |
|---|---|
| BP.L | BP (+42%) performed exceptionally well as Brent crude oil prices doubled to $118 a barrel. We don't own BP as a bet on the direction of oil prices. We own them because they sit at the centre of an essential system with hard-to-replicate infrastructure and capabilities. |
| SHEL.L | Shell (+32%) performed exceptionally well as Brent crude oil prices doubled to $118 a barrel. These aren't just upstream producers; they are operators of global networks linking supply to end demand – sourcing, shipping, refining, blending, storing, trading and distributing across regions, products and customers. |
| GAMA.L | Gamma Communications (-23%) serves to illustrate the fundamental disconnect between small and mid-cap company performance and valuation multiples. Gamma's share price performance came despite delivering 11% revenue and adjusted EPS growth in FY25, with a return of £64m of cash to shareholders. |
| DATA.L | GlobalData (-35%) was affected by market concerns around AI disruption to established business models, which was catalysed by Anthropic's January release of legal and marketing plug-ins for the Claude AI model. |
| CRW.L | Craneware (-30%) was affected by market concerns around AI disruption to established business models, which was catalysed by Anthropic's January release of legal and marketing plug-ins for the Claude AI model. |
| SGE.L | Sage Group (-22%) was affected by market concerns around AI disruption to established business models, which was catalysed by Anthropic's January release of legal and marketing plug-ins for the Claude AI model. |
| REL.L | RELX (-18%) was affected by market concerns around AI disruption to established business models, which was catalysed by Anthropic's January release of legal and marketing plug-ins for the Claude AI model. |
| GSK.L | GSK (+14%) shares strengthened after the company reported full-year 2025 results showing solid revenue and profit growth, driven primarily by strong performance in its Specialty Medicines portfolio, including oncology, HIV and respiratory treatments. |
| AZN.L | AstraZeneca (+7.6%) benefitted from a strong full-year 2025 results release, which demonstrated robust revenue growth and performance ahead of expectations, supported by strong demand across key therapy areas, particularly oncology. |
| TCAP.L | TP ICAP (+4.6%) typically shows some insulation from market turbulence since volumes in some of its business units benefit from periods of volatility. TP ICAP confirmed good trading in 2025, with episodic uncertainty driving spikes in volatility and strong activity in its over-the-counter division. |
| ATG.L | Auction Technology Group (ATG, +20%) was the latest to be targeted, revealing it had received and rejected a number of unsolicited, highly conditional proposals from its largest shareholder, FitzWalter Capital. The mooted takeover bid – raised to 400p/share – demonstrably failed to reflect the true value of this high-quality asset. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||